Scholarlink

<p>Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing <sup>18</sup>F-rhPSMA-7 or <sup>18</sup>F-flotufolastat (<sup>18</sup>F-rhPSMA-7.3)-PET-guided SRT compared with conventional-SRT (C-SRT) without PET. We evaluated biochemical failure-free survival (bFS) and overall rates of bFS in 110 evaluable patients with recurrent PC after radical prostatectomy who received SRT. 82 patients received <sup>18</sup>F-rhPSMA-7/<sup>18</sup>F-flotufolastat-PET-guided SRT and 28 received C-SRT. Median bFS for patients with <sup>18</sup>F-rhPSMA-7/<sup>18</sup>F-flotufolastat-PET-guided SRT was not reached while median bFS was 45.6 months for patients with C-SRT (<i>p</i> = 0.101). %bFS were 95% (52/55) <i>vs</i> 87% (20/23), 90% (27/30) <i>vs</i> 75% (15/20), 89% (16/18) <i>vs</i> 68% (13/19) and 100% (3/3) <i>vs</i> 57% (8/14) for PET-guided <i>vs</i> C-SRT at 12, 24, 36, and 48 months, respectively. Among patients treated in the prostate bed only, median bFS was not reached for PSMA-PET-guided SRT (n = 52) <i>vs</i> 55.1 months in the C-SRT group (n = 25; <i>p</i> = 0.063). %bFS was greater for PSMA-PET-guided SRT than C-SRT at all evaluated timepoints. <sup>18</sup>F-rhPSMA-7/<sup>18</sup>F-flotufolastat-guided SRT yielded favorable disease outcomes. Although statistical significance was not reached, likely due to the limited sample size in this preliminary analysis, our data illustrate potential for <sup>18</sup>F-flotufolastat-PET-guided SRT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月17日

查看全文
  • Marco M. E. Vogel,
  • Isabel Rauscher,
  • Jürgen E. Gschwend,
  • Türkay Hekimsoy,
  • Nicola Gabler,
  • Charlotte Olufs,
  • Calogero D’Alessandria,
  • Jan C. Peeken,
  • Stephanie E. Combs,
  • Matthias Eiber

摘要

Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing 18F-rhPSMA-7 or 18F-flotufolastat (18F-rhPSMA-7.3)-PET-guided SRT compared with conventional-SRT (C-SRT) without PET. We evaluated biochemical failure-free survival (bFS) and overall rates of bFS in 110 evaluable patients with recurrent PC after radical prostatectomy who received SRT. 82 patients received 18F-rhPSMA-7/18F-flotufolastat-PET-guided SRT and 28 received C-SRT. Median bFS for patients with 18F-rhPSMA-7/18F-flotufolastat-PET-guided SRT was not reached while median bFS was 45.6 months for patients with C-SRT (p = 0.101). %bFS were 95% (52/55) vs 87% (20/23), 90% (27/30) vs 75% (15/20), 89% (16/18) vs 68% (13/19) and 100% (3/3) vs 57% (8/14) for PET-guided vs C-SRT at 12, 24, 36, and 48 months, respectively. Among patients treated in the prostate bed only, median bFS was not reached for PSMA-PET-guided SRT (n = 52) vs 55.1 months in the C-SRT group (n = 25; p = 0.063). %bFS was greater for PSMA-PET-guided SRT than C-SRT at all evaluated timepoints. 18F-rhPSMA-7/18F-flotufolastat-guided SRT yielded favorable disease outcomes. Although statistical significance was not reached, likely due to the limited sample size in this preliminary analysis, our data illustrate potential for 18F-flotufolastat-PET-guided SRT.